OncoMatch/Clinical Trials/NCT06465433
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Is NCT06465433 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tafasitamab for hematologic malignancies.
Treatment: Tafasitamab — This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Demographics
Prior therapy
Must have received: tafasitamab (tafasitamab) — parent tafasitamab clinical study
Having been enrolled and is still receiving treatment with tafasitamab at the end of a parent tafasitamab clinical study
Cannot have received: tafasitamab (tafasitamab)
Has met one or more criteria for permanent tafasitamab treatment discontinuation as stipulated in the parent protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06465433 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior tafasitamab disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify